| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
PEG5-Tos does not have a specific biological target. It is a heterobifunctional PEG linker used in the synthesis of antibody-drug conjugates (ADCs) and PROTACs. The tosyl group is a good leaving group that can be displaced by nucleophiles, allowing for the attachment of various functional groups or drug molecules. The hydroxyl group can be further derivatized or used as a handle for conjugation. The PEG spacer increases the aqueous solubility of the resulting compound. PEG5-Tos is used as a PEGylating agent, capable of covalently attaching a short polyethylene glycol chain to a target molecule.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody using an ADC linker to form an ADC.
PEG5-Tos is not evaluated for direct biological activity in cell-based assays. It is a PEG linker used to improve the physicochemical properties of drug molecules and bioconjugates. The tosyl group allows for further derivatization. The PEG spacer increases the aqueous solubility of the resulting compound. PEG5-Tos is used in the synthesis of ADCs and PROTACs. |
| ln Vivo |
PEG5-Tos is not administered as a therapeutic agent. It is used as a PEG linker in the synthesis of antibody-drug conjugates (ADCs) and PROTACs. The PEG linker increases the water solubility and improves the pharmacokinetic properties of the conjugated molecules. PEG5-Tos's in vivo effects are related to its ability to improve the properties of conjugated drugs.
|
| Enzyme Assay |
PEG5-Tos does not have established receptor binding or enzyme inhibition assay protocols. Its properties are characterized by standard analytical methods including NMR, HPLC, and mass spectrometry. Physical properties: molecular weight 348.41 g/mol; molecular formula C15H24O7S; density 1.202 g/mL at 25°C. Purity: ≥95-98%. Solubility: Water and organic solvents. Storage: -20°C.
|
| Cell Assay |
Cellular studies with PEG5-Tos are not typically conducted as it is a linker molecule rather than a pharmacologically active agent. Its effects are assessed indirectly through the properties of the conjugated molecules. If used in cell-based research, it would be as a component of drug conjugates or as a control compound. Standard cell culture protocols would apply if cellular effects were to be evaluated.
|
| Animal Protocol |
In vivo studies are not conducted with PEG5-Tos as a standalone compound. It is used as a PEG linker in the synthesis of ADCs and PROTACs. The in vivo effects of PEG5-Tos are assessed indirectly through the properties of the conjugated molecules.
|
| ADME/Pharmacokinetics |
Molecular Weight: 348.41. Formula: C15H24O7S. CAS No.: 77544-60-6. IUPAC Name: 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate. Synonyms: Tetraethylene glycol monotosylate, Tos-PEG4. Purity: ≥95-98%. Density: 1.202 g/mL at 25°C. Solubility: Water and organic solvents. Storage: -20°C. PEG5-Tos is a heterobifunctional PEG linker used in ADC and PROTAC synthesis.
|
| Toxicity/Toxicokinetics |
No toxicology data are available for PEG5-Tos as it is a linker molecule rather than a pharmaceutical compound. The compound is intended for laboratory use only and is not intended for human consumption or therapeutic use. Standard safety precautions for handling chemicals should be followed.
|
| References |
[1]. Park KD, et al. Useful tools for biomolecule isolation, detection, and identification: acylhydrazone-based cleavable linkers.Chem Biol. 2009 Jul 31;16(7):763-72.
|
| Additional Infomation |
PEG5-Tos is also known as Tetraethylene glycol monotosylate, Tos-PEG4, and OH-PEG4-Tos. Its IUPAC name is 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate. PEG5-Tos is a heterobifunctional PEG derivative with a hydroxyl group and a tosyl group. It is used as a cleavable ADC linker and a PROTAC linker. The tosyl group is a good leaving group for nucleophilic substitution reactions. No clinical trials have been reported for this compound. PEG5-Tos is for research use only.
|
| Molecular Formula |
C15H24O7S
|
|---|---|
| Molecular Weight |
348.4119
|
| Exact Mass |
348.124
|
| CAS # |
77544-60-6
|
| PubChem CID |
13456094
|
| Appearance |
Colorless to light yellow viscous liquid
|
| LogP |
1.21
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
23
|
| Complexity |
372
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C([H])=C([H])C(C([H])([H])[H])=C([H])C=1[H])(=O)(=O)OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])O[H]
|
| InChi Key |
FGDJUEZBMFELRW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H24O7S/c1-14-2-4-15(5-3-14)23(17,18)22-13-12-21-11-10-20-9-8-19-7-6-16/h2-5,16H,6-13H2,1H3
|
| Chemical Name |
2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8702 mL | 14.3509 mL | 28.7018 mL | |
| 5 mM | 0.5740 mL | 2.8702 mL | 5.7404 mL | |
| 10 mM | 0.2870 mL | 1.4351 mL | 2.8702 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
